Feature

Stopping anti-TNF drugs in PsA has high rebound risk

Publish date: October 26, 2017

 

FROM JOURNAL OF RHEUMATOLOGY

Pages

Recommended Reading

First IL-23 blocker, guselkumab, earns FDA approval for psoriasis
MDedge Internal Medicine
FDA approves second adalimumab biosimilar for multiple conditions
MDedge Internal Medicine
New recommendations tout biosimilars for rheumatologic diseases
MDedge Internal Medicine
Adjuvant-boosted shingles vaccine earns FDA panel’s unanimous nod
MDedge Internal Medicine
Ultrasound’s value for arthralgia may be to rule out IA
MDedge Internal Medicine
Smoking linked to increased psoriasis risk
MDedge Internal Medicine
Launch of adalimumab biosimilar Amjevita postponed
MDedge Internal Medicine
High ‘nocebo’ effect observed when patients knowingly switch to a biosimilar
MDedge Internal Medicine
Biosimilars poised to save $54 billion over the next decade
MDedge Internal Medicine
Swedish study finds low risk of developing psoriasis in bariatric surgery patients
MDedge Internal Medicine

Related Articles